Press Release: NMRA IMPORTANT DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Neumora Therapeutics, Inc. Investors to Secure Counsel Before Important April 7 Deadline in Securities Class Action First Filed by the Firm – NMRA
NEW YORK, March 28, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Neumora Therapeutics, Inc. (NASDAQ: NMRA) pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Offering Documents”) issued in connection with Neumora’s September 2023 initial public offering (the “IPO”), of…
NEW YORK, Sept. 21, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sable Offshore Corp. (“Sable” or “the Company”) (NYSE: SOC) and certain of its officers.
DUBAI, United Arab Emirates, Sept. 21, 2025 (GLOBE NEWSWIRE) -- Mutuum Finance (MUTM), an Ethereum-based decentralized finance (DeFi) protocol, has raised over $16 million today. This traction is fueled by investor inflows supporting Mutuum Finance in its presale, backed by a completed CertiK smart contract audit, and its plans to launch a beta version of…
MILAN, Italy, Sept. 21, 2025 (GLOBE NEWSWIRE) -- LiTime, a global pioneer in new energy technology, made its first appearance at the 2025 Il Salone del Camper (September 13–21, Hall 02, Booth D006). The company showcased a lineup of best-selling flagship products and localized battery system solutions, with the spotlight on its H190 series of…
PARSIPPANY, N.J. and TEL AVIV, Israel, Sept. 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of data from a real-world survey of patients taking AUSTEDO XR® (deutetrabenazine) extended-release tablets. Patients taking AUSTEDO XR reported increased social and emotional well-being as…
NEW YORK, Sept. 20, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between May 7, 2025 and July 28, 2025, both dates inclusive (the “Class Period”), of the important September 30, 2025 lead plaintiff deadline.
